CoChat

Turning the corner on therapeutic cancer vaccines

Open access
Hollingsworth, Robert E., Jansen, Kathrin · 2019 · npj Vaccines

The DOI matches its Crossref record; 165 of the 165 references it cites were found in a registry or an index.

Abstract

Recent advances in several areas are rekindling interest and enabling progress in the development of therapeutic cancer vaccines. These advances have been made in target selection, vaccine technology, and methods for reversing the immunosuppressive mechanisms exploited by cancers. Studies testing different tumor antigens have revealed target properties that yield high tumor versus normal cell specificity and adequate immunogenicity to affect clinical efficacy. A few tumor-associated antigens, normal host proteins that are abnormally expressed in cancer cells, have been demonstrated to serve as good targets for immunotherapies, although many do not possess the needed specificity or immunogenicity. Neoantigens, which arise from mutated proteins in cancer cells, are truly cancer-specific and can be highly immunogenic, though the vast majority are unique to each patient’s cancer and thus require development of personalized therapies. Lessons from previous cancer vaccine expeditions are teaching us the type and magnitude of immune responses needed, as well as vaccine technologies that can achieve these responses. For example, we are learning which vaccine approaches elicit the potent, balanced, and durable CD4 plus CD8 T cell expansion necessary for clinical efficacy. Exploration of interactions between the immune system and cancer has elucidated the adaptations that enable cancer cells to suppress and evade immune attack. This has led to breakthroughs in the development of new drugs, and, subsequently, to opportunities to combine these with cancer vaccines and dramatically increase patient responses. Here we review this recent progress, highlighting key steps that are bringing the promise of therapeutic cancer vaccines within reach.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41541-019-0103-y

Cites

165 of 165 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Therapeutic cancer vaccine target types. Targets for tumor vaccines fall into two general classes: tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs). TAAs are self-antigens that are either preferentially or abnormally expressed in tumor cells, but may be expressed at some level in normal cells as well. As self-antigens, T cells that bind with high affinity to TAAs are typically deleted from the immune repertoire by central and peripheral tolerance mechanisms, and thus a cancer vaccine using these antigens must be potent enough to “break tolerance.” TSAs, comprised of antigens expressed by oncoviruses and neoantigens encoded by cancer mutations, are truly tumor-specific and as such high-affinity T cells may be present and strongly activated by these antigens. Although individual oncoviral antigens are expressed in specific tumor types (e.g., the HPV E6 and E7 antigens in cervical cancer), this occurs in many patients. Similarly, neoantigens encoded by oncogenic driver mutations may be prevalent across patients and tumor types, and hence are referred to as shared neoantigens. The majority of neoantigens are unique to individual patients’ tumors (private neoantigens), and thus require generation of a personalized therapy
Fig. 1 Therapeutic cancer vaccine target types. Targets for tumor vaccines fall into two general classes: tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs). TAAs are self-antigens that are either preferentially or abnormally expressed in tumor cells, but may be expressed at some level in normal cells as well. As self-antigens, T cells that bind with high affinity to TAAs are typically deleted from the immune repertoire by central and peripheral tolerance mechanisms, and thus a cancer vaccine using these antigens must be potent enough to “break tolerance.” TSAs, comprised of antigens expressed by oncoviruses and neoantigens encoded by cancer mutations, are truly tumor-specific and as such high-affinity T cells may be present and strongly activated by these antigens. Although individual oncoviral antigens are expressed in specific tumor types (e.g., the HPV E6 and E7 antigens in cervical cancer), this occurs in many patients. Similarly, neoantigens encoded by oncogenic driver mutations may be prevalent across patients and tumor types, and hence are referred to as shared neoantigens. The majority of neoantigens are unique to individual patients’ tumors (private neoantigens), and thus require generation of a personalized therapyCC BY · PubMed Central
Fig. 2 Mechanism of T cell activation and cancer cell killing. Activation of cytotoxic T cells (CTLs) depends on three signals: T cell receptor (TCR) engagement (signal 1), co-stimulation (signal 2), and an inflammatory stimulus (signal 3) via cytokines. T cell priming is initiated in tumor draining lymph nodes by specific binding of a TCR to its cognate peptide-major histocompatibility (MHC) complex displayed on an antigen-presenting cell (APC), particularly dendritic cells (DCs). This triggers a signaling cascade from the TCR complex that ultimately can regulate nuclear gene expression programs that transforms the T cell from a resting state to a state of activation and proliferation. Signal 1 alone, however, is insufficient for full activation, and the T cell must receive co-stimulation from the APC. Important co-stimulatory signals events include binding of the CD80 and CD86 ligands on APCs to the T cell CD28 receptor, and the binding of the OX40 and 4-1BB ligands to their receptors. TCR activation in the absence of co-stimulation can lead to T-cell anergy. In addition, co-stimulator ligands are depressed in tumors, and this can be overcome both by adjuvants that activate pattern recognition receptors on APCs, which upregulate expression of co-stimulatory ligands, and by antibodies that agonize the co-stimulatory receptors on T cells. Tumor cells also overexpress co-inhibitors, including CTLA-4 and PD-1, which normally function as T cell checkpoints to deactivate T cell activation after an infection is cleared. Antagonist antibodies have been developed to overcome this suppressive mechanism, and have demonstrated good clinical efficacy in some cancer types. Cytokines, including type I interferons and interleukin (IL)-12, provide the third necessary activation signal, and support the stimulation the expansion and differentiation of CD8 T cells into effector and memory CTLs. In addition, CD4 TH1 helper T cells can significantly amplify and sustain CTLs, primarily by supplying IL-2, whereas various other cells, including CD4 Treg cells, myeloid-derived suppressor cells (MDSCs), and M2-type tumor-associated macrophages (TAMs) can significantly dampen CTL activation and function. T cells must also migrate to and infiltrate the tumor, and tumors employ numerous countermeasures to block this. These include physical barriers created by abnormal vasculature and stromal cell build up, as well as disruption of chemokines that guide T cells to the tumor
Fig. 2 Mechanism of T cell activation and cancer cell killing. Activation of cytotoxic T cells (CTLs) depends on three signals: T cell receptor (TCR) engagement (signal 1), co-stimulation (signal 2), and an inflammatory stimulus (signal 3) via cytokines. T cell priming is initiated in tumor draining lymph nodes by specific binding of a TCR to its cognate peptide-major histocompatibility (MHC) complex displayed on an antigen-presenting cell (APC), particularly dendritic cells (DCs). This triggers a signaling cascade from the TCR complex that ultimately can regulate nuclear gene expression programs that transforms the T cell from a resting state to a state of activation and proliferation. Signal 1 alone, however, is insufficient for full activation, and the T cell must receive co-stimulation from the APC. Important co-stimulatory signals events include binding of the CD80 and CD86 ligands on APCs to the T cell CD28 receptor, and the binding of the OX40 and 4-1BB ligands to their receptors. TCR activation in the absence of co-stimulation can lead to T-cell anergy. In addition, co-stimulator ligands are depressed in tumors, and this can be overcome both by adjuvants that activate pattern recognition receptors on APCs, which upregulate expression of co-stimulatory ligands, and by antibodies that agonize the co-stimulatory receptors on T cells. Tumor cells also overexpress co-inhibitors, including CTLA-4 and PD-1, which normally function as T cell checkpoints to deactivate T cell activation after an infection is cleared. Antagonist antibodies have been developed to overcome this suppressive mechanism, and have demonstrated good clinical efficacy in some cancer types. Cytokines, including type I interferons and interleukin (IL)-12, provide the third necessary activation signal, and support the stimulation the expansion and differentiation of CD8 T cells into effector and memory CTLs. In addition, CD4 TH1 helper T cells can significantly amplify and sustain CTLs, primarily by supplying IL-2, whereas various other cells, including CD4 Treg cells, myeloid-derived suppressor cells (MDSCs), and M2-type tumor-associated macrophages (TAMs) can significantly dampen CTL activation and function. T cells must also migrate to and infiltrate the tumor, and tumors employ numerous countermeasures to block this. These include physical barriers created by abnormal vasculature and stromal cell build up, as well as disruption of chemokines that guide T cells to the tumorCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 165 references

Research works printed but not linked: 7

  1. Carreno BM Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells Science 2015 348 803 808 10.1126/science.aaa3828 25837513 PMC4549796 · DOI · Paper page
  2. Higano, C. et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). Genitourinary Cancers Symposium, LBA150 (2009).
  3. Small, E. et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). Genitourinary Cancers Symposium, a07 (2009).
  4. Santos PM Butterfield LH Dendritic cell-based cancer vaccines J. Immunol. 2018 200 443 449 10.4049/jimmunol.1701024 29311386 PMC5880540 · DOI · Paper page
  5. Aduro press release. http://investors.aduro.com/phoenix.zhtml?c=242043&p=irol-newsArticle&ID=2322291.
  6. Overwijk WW Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant Curr. Opin. Immunol. 2017 47 103 109 10.1016/j.coi.2017.07.015 28806603 · DOI
  7. Trimble CL Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial Lancet 2015 386 2078 2088 10.1016/S0140-6736(15)00239-1 26386540 PMC4888059 · DOI · Paper page

Cited by

See all 722

Metadata

Authors
Hollingsworth, R. E., & Jansen, K.
Affiliations
Pfizer (United States) (US)
Corresponding author
Jansen, Kathrin
Venue
npj Vaccines
Published
2019-02-08
Volume
4
Issue
1
Pages
7-7
ISSN
2059-0105 (ISSN-L)
OpenAlex
W2913400417
Cited by
689
References
165
Citations by year
2026: 30 · 2025: 71 · 2024: 100 · 2023: 83 · 2022: 120 · 2021: 161 · 2020: 101 · 2019: 23
FWCI
8.73
Type
journal article
Language
en
Open access
Licence
Locations
  • npj Vaccines (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
therapeutic cancer vaccines, tumor antigens, tumor-associated antigens, neoantigens, personalized cancer immunotherapy, vaccine immunogenicity, tumor specificity, tumor immunosuppression, tumor immune evasion, combination immunotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Turning the corner on therapeutic cancer vaccines. https://app.cochat.ai/papers/10.1038/s41541-019-0103-y
The paper
Hollingsworth, R. E., & Jansen, K. (2019). Turning the corner on therapeutic cancer vaccines. npj Vaccines. https://doi.org/10.1038/s41541-019-0103-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.